| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44020351 | HTLV-1 | ENSG00000152402.11 | protein_coding | GUCY1A2 | No | No | 2977 | P33402 |
| TVIS44033383 | HTLV-1 | ENSG00000152402.11 | protein_coding | GUCY1A2 | No | No | 2977 | P33402 |
| TVIS44017263 | HTLV-1 | ENSG00000152402.11 | protein_coding | GUCY1A2 | No | No | 2977 | P33402 |
| TVIS44012250 | HTLV-1 | ENSG00000152402.11 | protein_coding | GUCY1A2 | No | No | 2977 | P33402 |
| TVIS44046578 | HTLV-1 | ENSG00000152402.11 | protein_coding | GUCY1A2 | No | No | 2977 | P33402 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GUCY1A2 |
|---|---|
| DrugBank ID | DB00435 |
| Drug Name | Nitric Oxide |
| Target ID | BE0003578 |
| UniProt ID | P33402 |
| Regulation Type | inducer |
| PubMed IDs | 1852778; 20089135 |
| Citations | Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42.@@Mancuso C, Navarra P, Preziosi P: Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010 May;113(3):563-75. doi: 10.1111/j.1471-4159.2010.06606.x. Epub 2010 Jan 20. |
| Groups | Approved |
| Direct Classification | Other non-metal oxides |
| SMILES | [N]=O |
| Pathways | Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]; Ornithine Aminotransferase Deficiency (OAT Deficiency); Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Hyperprolinemia Type I; Hyperprolinemia Type II; Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency); Prolidase Deficiency (PD); Nitric Oxide Signaling Pathway; Arginine and Proline Metabolism; Hyperornithinemia with Gyrate Atrophy (HOGA); Prolinemia Type II; L-Arginine:Glycine Amidinotransferase Deficiency; Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency |
| PharmGKB | PA450635 |
| ChEMBL | CHEMBL1200689 |
